N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target. 2021

Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
Department of Urology, Xiangya Hospital, Central South University, Changsha, China.

N6-methylation of adenosine (m6A), a post-transcriptional regulatory mechanism, is the most abundant nucleotide modification in almost all types of RNAs. The biological function of m6A in regulating the expression of oncogenes or tumor suppressor genes has been widely investigated in various cancers. However, recent studies have addressed a new role of m6A modification in the anti-tumor immune response. By modulating the fate of targeted RNA, m6A affects tumor-associated immune cell activation and infiltration in the tumor microenvironment (TME). In addition, m6A-targeting is found to affect the efficacy of classical immunotherapy, which makes m6A a potential target for immunotherapy. Although m6A modification together with its regulators may play the exact opposite role in different tumor types, targeting m6A regulators has been shown to have wide implications in several cancers. In this review, we discussed the link between m6A modification and tumor with an emphasis on the importance of m6A in anti-tumor immune response and immunotherapy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D058990 Molecular Targeted Therapy Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease. Targeted Molecular Therapy,Molecular Targeted Therapies,Molecular Therapy, Targeted,Targeted Molecular Therapies,Targeted Therapy, Molecular,Therapy, Molecular Targeted,Therapy, Targeted Molecular
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments

Related Publications

Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
August 2023, Annals of hematology,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
January 2022, Frontiers in oncology,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
June 2021, Molecular therapy. Nucleic acids,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
December 2020, Biochemical pharmacology,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
November 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
June 2023, Trends in molecular medicine,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
November 2018, Oncology letters,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
February 2018, Current opinion in genetics & development,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
January 2020, Cell & bioscience,
Chao Quan, and Othmane Belaydi, and Jiao Hu, and Huihuang Li, and Anze Yu, and Peihua Liu, and Zhenglin Yi, and Dongxu Qiu, and Wenbiao Ren, and Hongzhi Ma, and Guanghui Gong, and Zhenyu Ou, and Minfeng Chen, and Yin Sun, and Jinbo Chen, and Xiongbing Zu
July 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Copied contents to your clipboard!